Evaluation of the role of ischemia modified albumin as a new biochemical marker for differentiation between ischemic and hemorrhagic stroke  by Gad, Mohamed Samy et al.
Alexandria Journal of Medicine (2015) 51, 213–217HO ST E D  BY
Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
http://www.elsevier.com/locate/ajmeEvaluation of the role of ischemia modiﬁed albumin
as a new biochemical marker for diﬀerentiation
between ischemic and hemorrhagic strokeAbbreviations: IMA, ischemia modiﬁed albumin; CT, computerized
tomography; CVA, cerebrovascular accident; HGE, hemorrhage
* Corresponding author.
E-mail addresses: mohsamyg@yahoo.com (M.S. Gad),
Nermeenhosam@yahoo.com (N.H.E.-D. Zakaria), dr_nany_hasan@
yahoo.com (N.H.A.A.-M. Elgayar).
Peer review under responsibility of Alexandria University Faculty of
Medicine.
http://dx.doi.org/10.1016/j.ajme.2014.08.006
2090-5068 ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.Mohamed Samy Gad a, Nermeen Hosam El-Din Zakaria b,
Nany Hassan Abu Al-Makarim Elgayar c,*a Geriatric Unit, Faculty of Medicine, Alexandria University, Egypt
b Chemical and Clinical Pathology Department, Faculty of Medicine, Alexandria University, Egypt
c Internal Medicine Department (Geriatric Unit), Faculty of Medicine, Alexandria University, EgyptReceived 15 April 2014; accepted 26 August 2014
Available online 6 March 2015KEYWORDS
Ischemia modiﬁed albumin
(IMA);
Hemorrhagic stroke;
Ischemic strokeAbstract Objective: To evaluate the role of the detection of ischemia modiﬁed albumin (IMA)
level in the differentiation between ischemic and hemorrhagic cerebrovascular stroke.
Methods: Sixty elderly persons classiﬁed into three groups, 25 patients diagnosed with cerebral
infarction, 15 patients diagnosed with cerebral hemorrhage, and 20 elderly healthy persons with
matched age as control were enrolled in the study. IMA was measured using the available chemical
method and computerized tomography (CT) was done for diagnosis of brain lesions.
Results: IMA was signiﬁcantly higher in the patient group than in the control group. There was a
positive signiﬁcant correlation between age, albumin with IMA, (P= 0.000 and 0.037 respectively).
However there was no statistical signiﬁcant difference between sex and diagnosis cross tabulation
(0.51). It was found that, IMA was statistically higher in the infarction group than the hemorrhage
group (P= 0.000) and IMD index was statistically higher in the infarction group than the hemor-
rhage group (P= 0.013).
Conclusion: Our investigation in elderly patients suggests that IMA assay is a sensitive marker for
early detection of ischemic and hemorrhagic stroke.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
A stroke, previously known medically as a cerebrovascular
accident (CVA) is the rabid loss of brain function(s) either
focal or global due to disturbance in the blood supply to the
brain, with symptoms lasting 24 h or longer or leading to death
with no apparent cause other than of vascular origin.1 The
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which is a related syndrome of stroke symptoms that resolve
completely within 24 h.2
The incidence of stroke increases exponentially from
30 years of age, and etiology varies by age.3 Advanced age is
one of the most signiﬁcant risk factors. 95% of strokes occur
in people aged 45 years and older, and two-thirds of strokes
occur in those over the age of 65 years. As the patient age
increases the risk of dying increases.4 Family members may
have a genetic tendency for stroke or share a lifestyle that con-
tributes to stroke.5
Stroke can be classiﬁed into two major categories: ischemic
and hemorrhagic. About 87% of strokes are caused by ische-
mia and the remainder by hemorrhage. Some hemorrhages
develop inside areas of ischemia (hemorrhagic transforma-
tion).6 In ischemic stroke, blood supply to part of the brain
is decreased, leading to dysfunction of the brain tissue in that
area. There are four main reasons why this might happen:
thrombosis (obstruction of a blood vessel by a blood clot
formed locally), embolism (obstruction due to embolus formed
elsewhere in the body),7 systemic hypo perfusion (general
decrease in the blood supply e.g. in shock) (global ischemia),8
and venous thrombosis. Stroke without an obvious explana-
tion is termed cryptogenic stroke and this constitutes 30–
40% of all ischemic strokes.9
As regards hemorrhagic stroke, it is caused by accumula-
tion of blood anywhere within the skull vault. A distinction
is made between intra-axial hemorrhage (blood inside the
brain either intra-parenchymal or intra-ventricular hemor-
rhages) and extra-axial hemorrhage (blood inside the skull
but outside the brain e.g. epidural hematoma, subdural hema-
toma, and subarachnoid hemorrhage).10
A growing body of investigation supporting the potential
of ischemia modiﬁed albumin (IMA) as a marker of ische-
mia is now available. Human serum albumin (HSA) is the
most abundant protein in the blood with a mean concentra-
tion of 0.63 mmol/L. It is synthesized in the liver and has a
half life of about 19 days. HSA has a unique structure and
amino acid sequence which is speciﬁc to humans at its
amino terminus (N-terminus).11 Previous studies have shown
the N-terminus of HSA to be the primary binding site for
the transitional metals cobalt and copper. The HSA metal
binding site is particularly susceptible to biochemical
changes during ischemia compared to albumin from other
species.12
The precise mechanisms for production of IMA during
ischemia are not known, but have localized modiﬁcation in
the amino terminal of HSA during ischemia which leads to
reduction in cobalt binding to this modiﬁed N-terminus.13
Many reports indicate that the factors involved in ischemia
that can induce these in vivo changes to albumin may include:
acidosis, free radical damage, membrane energy dependent
sodium and calcium pump disruption, reduced oxygen tension
and free iron and copper ion exposure.14 These conditions nec-
essary for altering the metal binding site of HSA are known to
occur within minutes of the onset of ischemia, and their effect
on albumin could be detectable up to 6 h after the ischemic
event.15
In the current study we tried to evaluate the detection of
ischemia modiﬁed albumin level in the differentiation between
ischemic and hemorrhagic cerebrovascular stroke.2. Methods
From May 2011 to January 2013, this study was conducted in
the Internal Medicine Department, Alexandria University
Hospital, Egypt; after being approved from the local
Research Ethics Committee, and informed consent was
obtained from all participants. We studied 40 elderly persons
recruited from the emergency department with a mean age of
49.0 ± 7.27 (range 40–75) years with cerebrovascular stroke
(Group I included 25 patients with cerebral infarction and
Group II included 15 patients with cerebral hemorrhage). In
addition, 20 apparently healthy elderly persons (Group III)
matched for age were included as controls. The exclusion crite-
ria included cardiac diseases, cancer, infections, end stage renal
disease, liver disease, uncontrolled diabetes mellitus and history
of treatment of thyroid disease. All subjects were subjected to:
1. Full history taking.
2. Complete clinical examination especially for signs of
cerebrovascular stroke (paresis, paralysis, loss of sensa-
tion, abnormal speech).
3. Radiological investigations: Computerized tomography
(CT) for diagnosis of brain lesions.
4. Blood samples were collected by venipuncture tubes
within two hours of arrival. These samples were sent
to the laboratory and processed for: routine laboratory
tests (liver function tests, renal function). Blood samples
were collected before any heparin/thrombolytic treat-
ment is started. Patients received routine institutional
care according to their diagnosis blinded to the IMA
results. IMA was measured using spectrophotometric
albumin cobalt binding assay. The assay is based on
the fact that ischemia causes changes in human serum
albumin that are demonstrated by reduced exogenous
cobalt binding. The concentration of IMA can be deter-
mined by addition of a known amount of exogenous
cobalt (CoCl2) to a serum specimen and measurement
of unbound cobalt using a colorimetric assay after add-
ing a coloring substance (dithiothreitol) which binds
any excess (unbound) cobalt. An inverse relationship
thus exits between the amount of albumin bound cobalt
and the intensity of the color formation. All reactions
were carried out at room temperature and in duplicate.
2.1. Test procedure
Addition of 200 lL of the patient serum, 50 lL of CoCl2, fol-
lowed by good mixing and incubation for 10 min were carried
out. Then 50 lL of DTT working solution (1.5 g/L DTT solu-
tion) was added and mixed. After a period of 2 min incubation,
1.0 ml of 9.0 g/L solution of NaCl was added. The absorbance
of this assay mixture was read at 470 nm using the 5010
Spectrophotometer (after reading the blank). Each sample
was read in duplicate, with average absorbance taken and
recorded in absorbance units (ABSU0) using PD-3035 Apel
Japan. As regards result interpretation: cases with absorbance
greater than 0.400 ABSU were considered positive for IMA,
while cases with absorbance less than 0.400 ABSU were con-
sidered negative for IMA. IMA index was calculated by using
Table 1 Diagnosis in relation to groups.
Diagnosis Number/percentage Control Patients Total
Control No. 20 0 20
% 100 0 33.3
HGE No. 0 15 15
% 0 37.5 25.0
Infarction No. 0 25 25
% 0 62.5 41.7
Total No. 20 40 60
% 100 100.0 100.0
v2 60.00
P .000
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tration (g/dl) · 23 + IMA (U/ml)  100)).
2.2. Statistical analysis
The clinical and laboratory results obtained are statistically
analyzed using SPSS/PC (version 4) (Statistical Package for
Social Science for Personal Computer). The value of LSD
(least signiﬁcant difference) indicates the difference within
the group, if LSD is more than the difference between the
mean of any two groups, it is an indication of signiﬁcance.
3. Results
Table 1 shows diagnosis in relation to groups. There was a sta-
tistical difference between control and patients regarding diag-
nosis (P= 0.000). Table 2 shows IMA ranged between 0.100
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Graph 1 Shows IMA levels in
Table 2 IMA and IMA index in the studied groups.
Data Groups Number Minimum Maxim
IMA Control 20 .10 .30
Patients 40 .23 .80
Total 60 .10 .80
IMA index Control 20 87.54 124.42
Patients 40 87.79 124.80
Total 60 87.54 124.80and 0.30 with the mean of 0.1872 ± 0.049 and
0.5083 ± 0.111 for control and patients respectively. The
patient group has statistically higher values than the control
group (P= 0.000) as shown in Graph 1. IMA index ranged
between 87.52–124.42 and 87.79–124.80 with the mean of
104.7223 ± 11.81 and 110.3908 ± 10.019 for control and
patient groups respectively. The patient group had statistically
higher values than the control group (P= 0.047) (see Graph 2).
Case processing summary (ROC curve);
Groups (b) positive (a) negative;
Valid N (list wise) 40 20.
Large values of the test result variable(s) indicate stronger
evidence for a positive actual state. (a) The positive actual state
is patients, (b) the test result variable: IMA has at least one tie
between the positive actual state group and the negative actual
state group.
Area under the curve
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Area .996;
Std error (a) 005;
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Graph 2 ROC curve.
216 M.S. Gad et al.Test result variables: IMA;
Positive if greater than or equal to (a) .2800
Sensitivity 975;
Speciﬁcity 050.
(a) The smallest cutoff value is the minimum observed test
value minus 1, and the largest cutoff value is the maximum
observed test value plus 1. All the other cutoff values are the
averages of two consecutive ordered observed test values.
Sex in relation to diagnosis cross-tabulation is found in
Table 3; it showed that there were no statistical signiﬁcant dif-
ferences between sex and diagnosis cross tabulation.
IMA ranged between 0.43–0.80 ABSU and 0.23–0.49 ABSU
with the mean of 0.5698 ± 0.0087 and 0.4059 ± 0.06033 for
infarction and hemorrhage respectively. The infarction group
has statistically higher values than the hemorrhage group
(P= 0.000). As regards IMA index, it ranged between
87.79–122.0 and 88.0–124.8 with the mean of 112.6 ± 6.98
and 107.6 ± 11.3 for infarction and hemorrhage respectively.Table 3 Sex in relation to diagnosis cross-tabulation.
Hemorrhage Infarction Total
Sex
Male No. 10 16 26
% 66.7 64.0 65.0
Female No. 5 9 14
% 33.3 36.0 35.0
Total No. 15 25 40
% 100.0 100.0 100.0
v2 0.864
P 0.51
Table 4 Shows relations between the diagnosis and IMA, IMA ind
Diagnosis N Mean S.D
IMA Infarction 25 .5698 .
HGE 15 .4059 .
IMA index Infarction 25 112.6 6.
HGE 15 107.6 11.The infarction group has statistically higher values than the
hemorrhage group (P= 0.013). These ﬁndings are represented
in Table 4.
4. Discussion
Gunduz et al.17 evaluated time course of IMA in acute
ischemic stroke (AIS) patients to validate its prognostic value.
IMA level was estimated in serum samples collected from ﬁve
AIS patients at admission, 24 h, 48 h, 72 h, and 144 h after
admission and also from ﬁve control subjects. There was a sig-
niﬁcant increase in IMA level in AIS samples at admission,
24 h, 48 h and 144 h respectively when compared with control.
On comparing IMA levels in follow up AIS samples with that
of admission values we found that it decreased in follow up
samples till 72 h, and a signiﬁcant (P< 0.05) decrease was
observed at 24 h and 72 h. Their ﬁndings show that follow
up estimation of IMA level in AIS may help in the prediction
of the clinical status and outcome. Also there was a positive
signiﬁcant correlation between IMA and age in this study.
IMA ranged between 0.43–0.80 and 0.23–0.49 with the mean
of 0.4059–0.06033 for infarction and hemorrhage respectively.
The infarction group has values statistically higher than the
hemorrhage group. Although IMA is a sensitive marker for
ischemia, as seen in our study, its sensitivity decreases especial-
ly in conditions associated with transient and reversible ische-
mia. Another factor responsible for these false negative IMA
values is the presence of lactic acid in these patients secondary
to prolonged ischemia and acidosis. Elevated lactic acid levels
have been shown to be associated with a decrease in IMA
levels, the cause of which is not known. The third possible
cause for false negative IMA, may be delayed presentation
to the ER.17
Few studies had assessed the role of IMA in stroke patients.
In the study of Gunduz et al. 8 patients in group B had an
elevated IMA in the absence of cardiac ischemia. Six of these
8 patients presented with features of transient ischemic attack
and progressed to develop ischemic stroke. However, their
IMA levels were elevated at the time of presentation. Chi-
square analysis revealed a signiﬁcant association of elevated
IMA levels with a diagnosis of ischemic stroke (P= 0.0029).
Our results were agreement in with a preliminary study by
Sameer et al. which showed that IMA is a biomarker for early
identiﬁcation of acute ischemic stroke.16
Mentese et al.18 reported that IMA concentrations are sig-
niﬁcantly lower immediately after exercise-induced leg ische-
mia in patients with peripheral vascular disease. Two
previous studies have assessed the effect of skeletal muscle
ischemia on serum IMA levels in apparently healthy indi-
vidual. A transient decrease in IMA concentration has been
observed immediately after exercise and/or skeletal muscleex.
. Min Max. T P
08715 .43 .80 40.991 .0001
06033 .23 .49
98 87.79 122.0 2.65 0.013
3 88.0 124.8
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been hypothesized that the immediate decrease may be
attributed to interference in the IMA measurement by lactate
produced during skeletal muscle ischemia.
Since susceptibility of the cells to ischemia may vary from
one organ to another, it would be critical to determine the
optimal IMA level for diagnosis of ischemia in various organs
especially the heart and the brain. Mentese et al.18 showed that
an increasing number of studies have shown that IMA levels
rise in a number of acute ischemic conditions such as cerebral
infarction, myocardial infarction, pulmonary infarction and
mesenteric infarction, suggesting that IMA may be useful as
a diagnostic marker. IMA is a promising marker to be consid-
ered for use in emergency department in conjunction with CT
brain for the diagnostic assessment of suspected stroke to
exclude stroke in patients with low clinical probability.19
5. Conclusion
IMA assay is a sensitive marker for early detection stroke. The
level of IMA is higher in ischemic stroke than hemorrhagic
stroke.
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